Abstract
ABSTRACT The TTD Group is a Spanish Cooperative Group with 28 years of history investigating and developing protocols in the digestive tumor field to improve healthcare quality. In the last decade, it research has been focused on the identification of biomarkers to improve and predict treatment outcomes. The MACRO (Maintenance in Colorectal Cancer) study was a phase III study to assess maintenance therapy with single-agent bevacizumab (B) versus B plus chemotherapy (QT) in patients (p) with metastatic colorectal cancer (mCRC). A post hoc analysis of the trial investigated the prognostic value of the circulating tumor cell (CTC) count and KRAS mutation status on patient outcomes and showed that both factors were independent prognostic factors for outcomes. Based on these results, the ongoing VISNU study will screen 750 p previously untreated with mCRC according to CTC count and gene status (RAS, BRAF y PI3K). In VISNU-1 trial (NCT01640405), 350 p with ≥ 3 CTC, will be randomized to receive FOLFOX-6 + B or FOLFOXIRI + B. In VISNU-2 trial (NCT01640444), 240 p with Disclosure: E. Aranda Aguilar: Honoraria or consultation fees: Roche and Merck.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
